While these factors have limited its generalized use, high-dose IL-2 serves as proof of principle that immunotherapies can eliminate tumor cells in some patients, encouraging efforts to develop better tolerated and more effective immunotherapy regimens. The gene discussed is IL2; the disease is neoplasm.